2022 discharge: European Medicines Agency
This procedure involves the European Parliament's review and approval of how the European Medicines Agency (EMA) managed its budget in 2022. The discharge process ensures that the agency used its funds transparently, efficiently, and in accordance with EU financial regulations.
This affects the European Medicines Agency's administration and accountability. A positive discharge confirms that the agency's financial management was satisfactory for the year.
Documents
2022 discharge: European Medicines Agency
proposal · EN · 2026-05-02
2022 discharge: European Medicines Agency
proposal · EN · 2026-05-02
2022 discharge: European Medicines Agency
report · EN · 2026-05-02
2022 discharge: European Medicines Agency
report · EN · 2026-05-02
2022 discharge: European Medicines Agency
proposal · EN · 2026-05-02
2022 discharge: European Medicines Agency
proposal · EN · 2026-05-02
2022 discharge: European Medicines Agency
proposal · EN · 2026-05-02
2022 discharge: European Medicines Agency
proposal · EN · 2026-05-02
2022 discharge: European Medicines Agency
proposal · EN · 2026-05-02
2022 discharge: European Medicines Agency
report · EN · 2026-05-02
2022 discharge: European Medicines Agency
report · EN · 2026-05-02
2022 discharge: European Medicines Agency
proposal · EN · 2026-05-02
2022 discharge: European Medicines Agency
proposal · EN · 2026-05-02
2022 discharge: European Medicines Agency
report · EN · 2026-05-02
2022 discharge: European Medicines Agency
report · EN · 2026-05-02
2022 discharge: European Medicines Agency
report · EN · 2026-05-02
2022 discharge: European Medicines Agency
report · EN · 2026-05-02
2022 discharge: European Medicines Agency
proposal · EN · 2026-05-02
2022 discharge: European Medicines Agency
proposal · EN · 2026-05-02
2022 discharge: European Medicines Agency
proposal · EN · 2026-05-02
2022 discharge: European Medicines Agency
proposal · EN · 2026-05-02
2022 discharge: European Medicines Agency
report · EN · 2026-05-02
2022 discharge: European Medicines Agency
proposal · EN · 2026-05-02
2022 discharge: European Medicines Agency
report · EN · 2026-05-02
2022 discharge: European Medicines Agency
proposal · EN · 2026-05-02
2022 discharge: European Medicines Agency
proposal · EN · 2026-05-02
2022 discharge: European Medicines Agency
report · EN · 2026-05-02
2022 discharge: European Medicines Agency
report · EN · 2026-05-02
2022 discharge: European Medicines Agency
report · EN · 2026-05-02
2022 discharge: European Medicines Agency
proposal · EN · 2026-05-02
2022 discharge: European Medicines Agency
proposal · EN · 2026-05-02
2022 discharge: European Medicines Agency
report · EN · 2026-05-02
2022 discharge: European Medicines Agency
report · EN · 2026-05-02
2022 discharge: European Medicines Agency
proposal · EN · 2026-05-02
2022 discharge: European Medicines Agency
report · EN · 2026-05-02
2022 discharge: European Medicines Agency
report · EN · 2026-05-02
2022 discharge: European Medicines Agency
report · EN · 2026-05-02
2022 discharge: European Medicines Agency
report · EN · 2026-05-02
2022 discharge: European Medicines Agency
report · EN · 2026-05-02
2022 discharge: European Medicines Agency
proposal · EN · 2026-05-02
2022 discharge: European Medicines Agency
proposal · EN · 2026-05-02
2022 discharge: European Medicines Agency
proposal · EN · 2026-05-02
2022 discharge: European Medicines Agency
report · EN · 2026-05-02
2022 discharge: European Medicines Agency
proposal · EN · 2026-05-02
2022 discharge: European Medicines Agency
proposal · EN · 2026-05-02
2022 discharge: European Medicines Agency
report · EN · 2026-05-02
2022 discharge: European Medicines Agency
proposal · EN · 2026-05-02
2022 discharge: European Medicines Agency
report · EN · 2026-05-02
2022 discharge: European Medicines Agency
proposal · EN · 2026-05-02
2022 discharge: European Medicines Agency
report · EN · 2026-05-02